$255,425 – $330,550
Listed on Gilead Sciences’s own careers site. You apply with them directly — we never stand between you and the employer.
What this role is
This executive role leads the end-to-end development of viral vectors for cell and gene therapies, managing both the technical strategy and a large interdisciplinary organization from early research through commercial manufacturing. It suits experienced bioprocess leaders with deep expertise in lentiviral systems who can balance scientific rigor with executive influence across a complex, matrixed environment.
Our summary, not Gilead Sciences’s wording. The full posting is on their site.
What they ask for
Required
- PhD in Biochemical Engineering, Molecular Biology, Virology, or related field with 15+ years of experience (or MS with 18+ years)
- Extensive experience in viral vector development and manufacturing for cell or gene therapy
- Demonstrated expertise in lentiviral and/or retroviral vector systems
- End-to-end experience from early development through commercialization
- Understanding of viral vector development across clinical phases, analytical strategies, and manufacturing considerations
- Experience leading cell therapy programs such as CAR-T
- Ability to lead in highly matrixed, cross-functional environments
- Track record of influencing portfolio and strategic decisions for drug development
Nice to have
- Exposure to in vivo gene delivery platforms
- Knowledge of retroviral vector development and CMC aspects